Supernus Pharmaceuticals
Open
$48.36
Prev. Close
$48.32
High
$48.36
Low
$48.30
Market Snapshot
$2.78B
-72.2
1.34
$661.82M
778
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
emptyResult
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Recently from Cashu
Supernus Pharmaceuticals Reports Strong Q4 Earnings and Optimistic Growth Outlook for 2026
Supernus Pharmaceuticals: A Strong Performance Drives Future Growth Outlook Supernus Pharmaceuticals announces its Q4 earnings results for 2026, showcasing impressive financial performance that reinfo…
Supernus Pharmaceuticals Reports Strong Q4 Earnings and Ambitious Growth Plans for 2027
Supernus Pharmaceuticals Achieves Strong Q4 Earnings and Signals Ambitious Growth Plans Supernus Pharmaceuticals, a company renowned for its innovative treatments in the neurological space, announces…
Supernus Pharmaceuticals Positioned for Growth with Strong Analyst Backing and Innovative Treatments
Supernus Pharmaceuticals: A Rising Star in the Pharmaceutical Sector Supernus Pharmaceuticals is gaining recognition for its potential growth as it attracts attention from analysts, particularly Bank…
Supernus Pharmaceuticals Enhances Neurological Disorder Treatments with Promising Pipeline and Collaborations
Supernus Pharmaceuticals Advances Treatment Options for Neurological Disorders Supernus Pharmaceuticals, a key player in the development of innovative therapies for central nervous system (CNS) disord…